Review
Published on 10 Nov 2022
Measurable residual disease in hairy cell leukemia: Technical considerations and clinical significance
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2022.976374
- 3,076 views
- 1 citation
Type at least 3 characters
1,688 articles
Articles
Original Research
Published on 10 Nov 2022
A phase I dose-escalation study of neoantigen-activated haploidentical T cell therapy for the treatment of relapsed or refractory peripheral T-cell lymphoma
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2022.944511
- 1,408 views
- 3 citations
Review
Published on 09 Nov 2022
Dysregulation of FBW7 in malignant lymphoproliferative disorders
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2022.988138
- 2,006 views
- 1 citation
Editorial
Published on 07 Nov 2022
Editorial: Real-World evidence in onco-hematological patients
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2022.1060802
- 1,001 views
Original Research
Published on 07 Nov 2022
NK cells with decreased expression of multiple activating receptors is a dominant phenotype in pediatric patients with acute lymphoblastic leukemia
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2022.1023510
- 2,334 views
- 6 citations
Review
Published on 03 Nov 2022
The 8p11 myeloproliferative syndrome: Genotypic and phenotypic classification and targeted therapy
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2022.1015792
- 3,909 views
- 4 citations
Review
Published on 02 Nov 2022
Acquired and hereditary bone marrow failure: A mitochondrial perspective
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2022.1048746
- 3,418 views
- 7 citations
Original Research
Published on 31 Oct 2022
Activity and rational combinations of a novel, engineered chimeric, TRAIL-based ligand in diffuse large B-cell lymphoma
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2022.1048741
- 2,442 views
- 2 citations
Editorial
Published on 31 Oct 2022
Editorial: Novel mechanisms for the treatment of AML before and after transplant
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2022.1063307
- 849 views
Case Report
Published on 31 Oct 2022
Acute necrotizing encephalopathy associated with lymphoma-associated hemophagocytic lymphohistiocytosis: A case report and literature review
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2022.986957
- 1,299 views
- 1 citation
Original Research
Published on 31 Oct 2022
Mass cytometry analysis reveals attrition of naïve and anergized self-reactive non-malignant B cells in chronic lymphocytic leukemia patients
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2022.1020740
- 1,770 views
- 2 citations
Review
Published on 28 Oct 2022
Navigating the contested borders between myelodysplastic syndrome and acute myeloid leukemia
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2022.1033534
- 4,750 views
- 5 citations
Editorial
Published on 27 Oct 2022
Editorial: Characteristics and behaviors of hematopoietic stem cells and leukemia stem cells in hematologic malignancies
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2022.1037202
- 935 views
Systematic Review
Published on 27 Oct 2022
The prognostic value of Epstein−Barr virus infection in Hodgkin lymphoma: A systematic review and meta-analysis
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2022.1034398
- 2,405 views
- 5 citations
Review
Published on 27 Oct 2022
Hemophagocytic lymphohistiocytosis as an etiology of bone marrow failure
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2022.1016318
- 7,119 views
- 5 citations
Review
Published on 27 Oct 2022
The path towards consensus genome classification of diffuse large B-cell lymphoma for use in clinical practice
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2022.970063
- 2,988 views
- 2 citations